China wins twice from Chi-Med's cancer milestone

With the approval of Elunate (fruquintinib), China not only has a promising new option for colorectal cancer (CRC), a disease diagnosed in around 380,000 new Chinese people each year.

The country can also boast that the approval is evidence of the increasing strength of its biopharma industry as Elunate is the first cancer drug to be unconditionally approved that was discovered and developed in China.

"This is the result of over a dozen years of steadfast commitment by Chi-Med in research and development in China’s emerging biotech ecosystem"